INCYIncyte CorporationFinished
A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor
Lymphoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 162 (final count)
- Started
- Nov 20, 2017
- Main results expected
- Apr 30, 2024
- Fully finished
- Apr 30, 2024
- Results posted
- Feb 10, 2022
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate (ORR)
Measured over: Up to 1016 days
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03235544 · record last updated 2025-03-18 · checked 2026-11-09 15:42 UTC